FY2026 Earnings Estimate for BMY Issued By Cantor Fitzgerald

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Cantor Fitzgerald boosted their FY2026 earnings estimates for shares of Bristol Myers Squibb in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will earn $6.15 per share for the year, up from their previous estimate of $6.06. Cantor Fitzgerald has a “Neutral” rating and a $55.00 price target on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the prior year, the firm posted $2.07 EPS. Bristol Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year.

Several other research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Jefferies Financial Group dropped their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Citigroup dropped their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, August 1st. Finally, Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $56.38.

Bristol Myers Squibb Stock Up 1.3%

BMY opened at $48.45 on Thursday. The firm has a 50-day simple moving average of $47.23 and a two-hundred day simple moving average of $51.50. Bristol Myers Squibb has a 52 week low of $42.96 and a 52 week high of $63.33. The company has a market capitalization of $98.62 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 2.44 and a beta of 0.36. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is 100.00%.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marcum Wealth LLC increased its position in shares of Bristol Myers Squibb by 1.0% during the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company’s stock worth $1,177,000 after acquiring an additional 193 shares during the period. Beacon Investment Advisory Services Inc. boosted its stake in shares of Bristol Myers Squibb by 2.7% during the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 212 shares in the last quarter. Exchange Capital Management Inc. boosted its stake in shares of Bristol Myers Squibb by 0.4% during the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock valued at $2,541,000 after purchasing an additional 220 shares in the last quarter. 1858 Wealth Management LLC boosted its stake in Bristol Myers Squibb by 3.6% in the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 221 shares in the last quarter. Finally, Parsons Capital Management Inc. RI boosted its stake in Bristol Myers Squibb by 0.3% in the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock valued at $3,615,000 after acquiring an additional 224 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.